31 results about "Anti hyperlipidemic" patented technology

A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and / or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and / or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and / or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and / or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.

The invention relates to new application of borapetoside E for preventing and treating diabetes and hyperlipemia. A research discovers that a compound borapetoside E is capable of obviously reducing the level of blood sugar and blood lipid of HFD (High Fat Diet) induced mice and improving insulin sensitivity of the HFD induced mice. The hypoglycemic and anti-hyperlipidemic effects of 40mg / kg of the compound borapetoside E are superior to those of 200mg / kg of metformin. In addition, the duration time of the hypoglycemic effect is longer than that of 200mg / kg of the metformin, the hypoglycemic effect after drug discontinuance of single drug administration of 40mg / kg of the compound borapetoside E continues for 36 hours, and the duration time after the drug discontinuance of five times of drug administration continues for 4 days. The borapetoside E under the therapeutic dosage has no toxic and side effects, the serum glutamic pyruvic transaminase level is remarkably reduced after successive administration is carried out on the mice for 16 days, serum glutamic oxalacetic transaminase, creatine kinase and creatinine are not obviously changed, and the borapetoside E can be used for preparing drugs, healthcare products and functional food for preventing and treating the diabetes.

Interaction of a specific viral domain with phosphatidylinositol 4,5-bisphosphate (PIP-2) is shown to mediate viral replication. Basic Amino Acid PIP-2 Pincer (BAAPP) domains are described herein, including, without limitation, NS5A protein of HCV, NS4B protein of HCV, poliovirus, and rhinovirus.